Gravity Analytica

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CYTK 01.06.2025

SERA-AI Powered Highlights

Drug:unknown aficamten

Drug:unknown omecamtiv mecarbil

Drug:unknown CK-586

Drug:unknown CK-089

Diseases:obstructive hypertrophic cardiomyopathy (HCM)

Diseases:heart failure with severely reduced ejection fraction (HFrEF)

Diseases:heart failure with preserved ejection fraction (HFpEF)

Diseases:specific type of muscular dystrophy

Date of Upcoming Event:2025-01-13

Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

Full Press Release SEC Filings Our CYTK Tweets

About Gravity Analytica

Recent Filings

SOUTH SAN FRANCISCO, Calif.,Jan. 06, 2025(GLOBE NEWSWIRE) --Cytokinetics, Incorporated(Nasdaq: CYTK) today announced thatRobert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43^rdAnnualJ.P. Morgan Healthcare ConferenceonMonday, January 13, 2025at9:00 AM Pacific Timein theBorgia Roomof theWestin St. Francis HotelinSan Francisco, CA.

Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of theCytokineticswebsite athttp://www.cytokinetics.com. The webcast replay will be archived on theCytokineticswebsite for 90 days following the conclusion of the event.

AboutCytokinetics

Cytokineticsis a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility.Cytokineticsis readying for the potential commercialization ofaficamten,a next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM).Aficamtenis also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM.Cytokineticsis also developingomecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct fromaficamten,for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information aboutCytokinetics, visitwww.cytokinetics.comand follow us onX,LinkedIn,FacebookandYouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").Cytokineticsdisclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating toCytokinetics'and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related toCytokinetics'business outlined inCytokinetics'filings with theSecurities and Exchange Commission. Forward-looking statements are not guarantees of future performance, andCytokinetics'actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements thatCytokineticsmakes in this press release speak only as of the date of this press release.Cytokineticsassumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and theCYTOKINETICSand C-shaped logo are registered trademarks ofCytokineticsin theU.S.and certain other countries.

Contact:CytokineticsDiane WeiserSenior Vice President, Corporate Affairs(415) 290-7757

Source: Cytokinetics, Incorporated

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com